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Background: Age-related macular degeneration (AMD) is a leading cause of blindness. Most vision loss occurs
following the transition from a disease of deposit formation and inflammation to a disease of neovascular fibrosis
and/or cell death. Here, we investigate how repeated wound stimulus leads to seminal changes in gene expression
and the onset of a perpetual state of stimulus-independent wound response in retinal pigmented epithelial (RPE)
cells, a cell-type central to the etiology of AMD.
Methods: Transcriptome wide expression profiles of human fetal RPE cell cultures as a function of passage and
time post-plating were determined using Agilent 44 K whole genome microarrays and RNA-Seq. Using a systems level
analysis, differentially expressed genes and pathways of interest were identified and their role in the establishment of a
persistent mesenchymal state was assessed using pharmacological-based experiments.
Results: Using a human fetal RPE cell culture model that considers monolayer disruption and subconfluent culture
as a proxy for wound stimulus, we show that prolonged wound stimulus leads to terminal acquisition of a
mesenchymal phenotype post-confluence and altered expression of more than 40 % of the transcriptome. In
contrast, at subconfluence fewer than 5 % of expressed transcripts have two-fold or greater expression differences
after repeated passage. Protein-protein and pathway interaction analysis of the genes with passage-dependent
expression levels in subconfluent cultures reveals a 158-node interactome comprised of two interconnected
modules with functions pertaining to wound response and cell division. Among the wound response genes are
the TGFβ pathway activators: TGFB1, TGFB2, INHBA, INHBB, GDF6, CTGF, and THBS1. Significantly, inhibition of
TGFBR1/ACVR1B mediated signaling using receptor kinase inhibitors both forestalls and largely reverses the
passage-dependent loss of epithelial potential; thus extending the effective lifespan by at least four passages.
Moreover, a disproportionate number of RPE wound response genes have altered expression in neovascular and
geographic AMD, including key members of the TGFβ pathway.
Conclusions: In RPE cells the switch to a persistent mesenchymal state following prolonged wound stimulus is driven
by lasting activation of the TGFβ pathway. Targeted inhibition of TGFβ signaling may be an effective approach towards
retarding AMD progression and producing RPE cells in quantity for research and cell-based therapies.* Correspondence: monte.radeke@lifesci.ucsb.edu
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Wound responses encompass a wide range of processes
directed at repairing tissue and cell damage. In vivo,
wound responses are often secondary or bystander re-
sponses that occur as a result of damage to neighboring
cells or tissue, however they can also occur at the single-
cell level [1]. The source of damage can be physical
trauma, microbial or viral infection, exposure to envir-
onmental toxins, genetically based dysfunction, or de-
generative disease. The nature of the trauma can be
acute or chronic. Some of the signals that can initiate
wound responses are disruption of cell-cell contacts, loss
of cell-substrate contacts, and exposure to blood compo-
nents. In addition, innate inflammatory responses play a
critical role in both the activation and orchestration of a
wound response [2]. Wound response inactivation re-
quires cessation of damage, wound closure, resolution of
the inflammatory response, and tissue remodeling or re-
generation. When the precipitating insult or injury is sus-
tained, a chronic aberrant wound response can ensue and
result in progressive disease; as is the case in chronic ob-
structive pulmonary disease or hepatitis-associated liver fi-
brosis [3, 4]. Although the core processes of wound repair
are common to all tissues, there can be substantial differ-
ences depending on the extent and nature of the insult, as
well as the affected tissues and cell types.
Fibrosis and uncontrolled neovascularization are com-
ponents of several blinding disorders [5]. One of those
diseases is age-related macular degeneration (AMD), a
progressive disorder affecting the central region of the
retina-choroid tissue complex. It is the leading cause of
blindness for Caucasians in the United States [6], with
6.5 % of the total population aged 40 years and older
having symptoms of AMD to some degree [7]. Dysfunc-
tion of the retinal pigmented epithelium (RPE) is gener-
ally considered to be central to the etiology of AMD.
The RPE is a simple cuboidal monolayer that separates
the neural retina from the highly vascular choroid. In
addition to regulating the transport of metabolites and
catabolites between the vascular system and the neural
retina, the RPE performs a number of unique functions
essential for the visual process and the maintenance of
the photoreceptors.
The first clinically recognized signs of AMD are the
accumulation of macular extracellular deposits, named
drusen, located between the RPE and Brüch’s membrane,
a multilayer extracellular matrix separating the RPE
from the choroid. As the disease progresses the number
and size of the drusen increase, RPE cells associated with
drusen can lose their epithelial morphology, and there
can be focal decreases or increases in RPE-associated
pigment. During these initial stages of the disease, classi-
fied as early AMD [8–10], there is minimal perceptible
loss of vision. Prominent loss of vision is only associatedwith late or advanced AMD, which is characterized by
macular RPE atrophy with associated neural retina atro-
phy and/or fibrotic subretinal choroidal neovasculariza-
tion. The former is referred to as geographic atrophy (GA)
and comprises 8 % of the AMD population. The latter is
classified as exudative or choroidal neovascular AMD
(CNV) which affects 5 % of those with AMD [7].
The transition from early to advanced AMD has features
consistent with the onset of an aberrant wound response
resulting from an underlying degenerative disease and
chronic inflammation. Drusen disrupt the normal tissue
architecture, disrupt function by impeding transport be-
tween the RPE and choroid, and are sites of activation of
the complement system [11, 12]. While the principal
cause(s) of AMD that results in accumulation of drusen is
debated, upwards of 75 % of AMD cases are associated
with polymorphisms in components of the complement
cascade [13], and cellular immune responses have been
shown to be part of the AMD gene expression signature
common to early AMD, GA, and CNV [14].
Here we report findings directed at furthering our un-
derstanding of the molecular basis of RPE wound re-
sponse, its likely impact on RPE function, and possible
role in AMD. Using a cell culture model system that con-
siders prevention of monolayer formation as a surrogate
for persistent wounding, coupled with a systems biology
founded transcriptome analysis, we identify changes in ex-
pression in a number of genes encoding products that play
a role in wound response or the cell cycle. Furthermore,
using a pharmacological approach we determine that pro-
longed wound stimulus results in permanent activation of
the TGFβ pathway that is independent of further wound
stimulus. Finally, we investigate the possible role for
wound responses in AMD by comparing the changes in
gene expression in this cell culture model to previously re-
ported AMD-associated gene expression changes.
Methods
Fetal RPE culture
RPE cells were isolated from fetal donor eyes (Advanced
Biosciences Resources, Alameda, CA, USA) according to
the methods of Hu and Bok [15, 16]. Beyond the initial
isolation, all cell culture was carried out using a base
medium described by Maminishkis et al. [17]. For 2–3
days post-plating the medium included 15 % heat inacti-
vated fetal calf serum. Thereafter, it was reduced to 5 %.
To generate a working cell bank, primary fetal RPE
stocks were expanded approximately ten-fold and these
working stocks were designated Passage 0 (P0). For rou-
tine serial passage, cells were harvested using trypsin di-
gestion and plated at 4,000 cells/cm2. At approximately
80 % confluence (every 3–5 days depending on passage
number) the cells were enzymatically harvested and re-
seeded at 4,000 cells/cm2. Cultures were carried out on
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Technologies, Grand Island, NY, USA; Millicell-HA
Culture Inserts, EMD Millipore Inc., Billerica, MA,
USA) or laminin-coated tissue culture plastic as indi-
cated. All cultures were fed every 2–4 days by complete
exchange of the medium.
The human tissue used in this study was obtained by
Advanced Biosciences Resources, (Alameda, CA, USA)
with informed consent and in accordance with the
World Medical Association Declaration of Helsinki and
local legislation. The collection of the tissue by Advanced
Bioscience Resources was evaluated and approved by the
Western Institutional Review Board. No information relat-
ing to the identity of the donors was provided by
Advanced Biosciences Resources.
Microarray analysis
Total RNA was purified using miRNeasy mini-preps
(Qiagen Inc., Valencia, CA, USA) and transcriptome
profiles were determined using the Agilent Whole
Human Genome 4 × 44 K in situ oligonucleotide plat-
form (G4112F, Agilent Technologies, Inc., Santa Clara,
CA, USA) and a two-color experimental design accord-
ing to the methods of the manufacturer. After global
background subtraction and Lowess normalization to
correct for non-linear dye effects, the net intensities
were determined by subtraction of the average value for
the negative control probes. For the 200 probes with 10
replicates the average intensity was determined and the
entire dataset was then quantile normalized. Detailed
microarray methods, sample details, and data can be
accessed through the Gene Expression Omnibus (GEO:
GSE67899). Prior to statistical or bioinformatics analysis,
probes that did not correspond to a known gene (as de-
fined by an assignment of a HUGO gene symbol) and
probes with an average signal intensity less than twice
background in all samples were discarded. For those
genes represented by multiple unique probes, the probe
with the highest average intensity was selected.
RNA-Seq analysis
Poly(A) + RNA was purified from 1 μg of total RNA
using the Magnetic mRNA Isolation Kit (New England
Biolabs, Inc., Ipswich, MA, USA) and then used to gen-
erate RNA-Seq libraries using the Ion Total RNA-Seq
Kit V2 (Life Technologies, Inc., Grand Island, NY, USA).
The resulting libraries were sequenced on Ion PGM or
Ion Proton next-generation sequencers. Sequence results
were aligned to the human transcriptome and genome
(hg38) using a two-stage pipeline employing TopHat2
[18] and TMAP (Life Technologies, Inc.) read aligners.
The number of reads per protein coding mRNA was de-
termined using Partek Genomics Suite (Partek Inc., St.
Louis, MO, USA) and the dataset was normalized usingthe trimmed mean of the M-values method [19]. Genes
with read counts per million (RPM) ≥1 in three or more
samples were selected and differential expression and
statistical analysis was carried out using edgeR [20, 21].
The RNA-Seq data and detailed methods can be
accessed through the Gene Expression Omnibus (GEO:
GSE67899).
Bioinformatics analysis
Cluster analysis was carried out on range centered log
transformed data using AutoSOME 2.1 (500 ensemble
runs, P = 0.03, unit variance, sum of squares = 1, and
precision settings) [22]. Individual clusters were assigned
to general groups following visual examination of the ex-
pression patterns. Gene ontology enrichment analysis
was performed using David 6.7 and default settings [23,
24]. Enrichment for RPE signature genes was carried out
manually using the combined RPE gene lists reported by
Strunnikova et al. [25] and Booij et al. [26]. Interaction
analysis was accomplished using STRING 9.1 [27] using
a medium confidence setting and the Experiment and
Databases prediction methods. The resulting network
was manually rendered using Cytoscape 3.0.2 [28].
The assessment of the involvement of RPE wound re-
sponse in AMD was carried out using the macular,
extramacular, and combined macular-extramacular
RPE-choroid and retina AMD gene list published by
Newman et al. ([14], Additional file 1: Table S1). Redun-
dant probes for the same gene in an AMD disease class
were eliminated and AMD genes among the 13,791
genes with above background expression in P0 or P5
RPE cells were identified. AMD-Up genes expressed in
RPE cells were cross-referenced with a list of 2,684
genes with increased expression in P5 RPE cells. RPE
expressed AMD-Down genes were matched to the 2,856
genes with decreased expression following passage. Differ-
ential expression was defined as having a 1.5-fold or
greater change in expression in all three donor cultures
and a minimum average fold change of 2.0 as a function
of passage in at least one of the four different time points
examined. Enrichment odds ratios and P values were de-
termined using Fisher’s exact test and the aforementioned
values for the sizes of the P5-Up and P5-Down gene sets
and the expressed RPE cell genome.
Real-time quantitative PCR
Real-time quantitative PCR (RT-qPCR) was performed
using PrimeTime® PCR Assays (Integrated DNA Tech-
nologies, Inc., Coralville, IA, USA). Assay information is
provided in Additional file 1: Table S1. For each sample,
cDNA was generated from total RNA using the iScript
cDNA Synthesis Kit (Bio-Rad Laboratories, Inc., Hercules,
CA, USA). For each gene of interest, RT-qPCR was carried
out in duplicate using iTaq Universal Probes Supermix
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45 × (95 °C for 5 s, 60 °C for 1 min). Gene expression
levels were calculated assuming a PCR efficiency of 100 %
and normalized to the geometric mean of three house-
keeping genes (RPL15, NDUFA11, and UBB) whose ex-
pression levels were found to be constant based on the
microarray analysis and the PCR analysis methods of
Vandesompele et al. [29].
Immunocytochemistry
Cells cultured on microporous inserts were fixed with 4 %
paraformaldehyde in phosphate buffered saline (PBS) for
10 min, after which they were transferred to 0.4 % parafor-
maldehyde in PBS and stored at 4 °C. In preparation for
immunolabeling, portions of insert were excised, rinsed
with PBS, and incubated in PBS containing 1 mg/mL bo-
vine serum albumin and 0.1 % Triton X-100 (PBT) with
5 % normal donkey serum to block non-specific binding.
Following a brief wash in PBT, the specimens were incu-
bated overnight with primary antibody diluted in PBT. In
those cases where unlabeled primary antibodies were used,
the specimens were washed in PBT and incubated with
fluorescently labeled secondary antibodies for 4 h. The
specimens were then washed with PBT followed by stain-
ing with Alexa Flour 488 phalloidin and Hoescht 33342 to
label actin filaments and DNA. Images of the labeled cells
were collected using laser scanning confocal microscopy.
The antibodies used in this study and their dilutions were:
mouse anti-ACTA2, 1:500 (#MA5-15871: ThermoScienti-
fic, Waltham, MA, USA); rabbit anti-BEST1, 1:300
(#5466: EMD Millipore, Temecula, CA, USA); mouse
anti-PMEL, 1:50 (#M0634: Dako, Carpenteria, CA, USA);
Alexa Fluor 594 mouse anti-TJP1, 1:100 (#339194: Life
Technologies); Alexa Fluor 546 donkey anti-mouse IgG,
1:200 (#A10036: Life Technologies); Alexa Fluor 647
donkey anti-mouse IgG(H + L), 1:200 (#A31571: Life
Technologies); and Alexa Fluor 647 donkey anti-rabbit
IgG(H + L), 1:200 (#A31573: Life Technologies).
Results
Prolonged subconfluent culture results in loss of the
epithelial phenotype
It has been appreciated for some time that primary RPE
cells, like many cells, undergo a permanent switch in
phenotype with repeated passage [30]. Minimally passaged
cultured RPE cells have a non-epithelial morphology rem-
iniscent of fibroblasts while they are subconfluent and mi-
totically active. It is only after they reach confluence that
they attain an epithelial morphology and begin to accumu-
late pigment. The change in epithelial to fibroblast-like
phenotype is commonly referred to as an epithelial-to-
mesenchymal transition (EMT) and is a component of de-
velopment and successful wound repair where the cells
return to their normal differentiated state via amesenchymal-to-epithelial transition. However, with re-
peated passage at sub-confluence there is a marked de-
crease in the capacity to pigment (Fig. 1a) and to acquire
an epithelial morphology (Fig. 1b) post-confluence. In
addition to a passage-dependent loss of potential to differ-
entiate, minimally passaged RPE cells also fail to differ-
entiate when seeded at low density (Fig. 1c). Repeated
passage also results in a decreased rate of cell doubling, a
lower final cell density, and loss of cells post-confluence
(Additional file 2: Figure S1).
Passage-induced changes in phenotype are accompanied
by wholesale changes in gene expression
To gain insight into the molecular basis of the pheno-
typic switch, we carried out a whole transcriptome ana-
lysis of RPE as a function of passage and time in culture.
Passage 0 (P0) and Passage 5 (P5) RPE cells from three
different donors were plated at a density conducive to
differentiation and maintained in culture for 16, 32, and
64 days. In addition, P0 and P5 cultures were seeded at
low density and collected after 3 days while still subcon-
fluent. Genome-wide transcriptome profiles were then
determined by microarray analysis. Of the 19,595 non-
redundant RefSeq genes represented on the microarrays,
nearly 13,800 had detectable levels of expression as defined
by net signal intensities greater than twice the estimated
background. To identify genes that were differentially
expressed, a fold change criteria was employed requiring
each intra-donor pairwise comparison to have a fold
change of ≥1.5 and the mean fold change for all donors to
be ≥2.0. When this criterion was applied to all possible
inter-donor comparisons within a condition it was deter-
mined that the number of differences expected by random
chance ranged from 2 (3-day P0) to 77 (16-day P5).
Over two-thirds of the genes with detectable signals had
two-fold or greater differences in expression as a function
of passage or time in culture. Nearly 5,500 genes had ex-
pression differences as a function of passage alone. To bet-
ter categorize the differentially expressed genes they were
arranged into groups based on their expression profiles
using AutoSOME [22], an assumption-free clustering
method (Fig. 2). Three major expression profile categories
were identified. The first (Groups a-c) consists of genes that
are preferentially expressed in differentiation-competent
(P0) cells. The second category (Groups d and e) is
comprised of genes that are most highly expressed in
differentiation-incompetent (P5) cells. Group d is primarily
comprised of genes that are expressed in subconfluent cells
and fail to turn off in confluent P5 cells. Group e contains
genes preferentially expressed in confluent P5 cells. The last
category (Groups f and g) is made up of genes whose ex-
pression correlates with the state of confluence. A listing of
the genes associated with these expression groups and the
associated data is provided in Additional file 3: Table S2.
Fig. 1 Sustained subconfluent culture results in the loss of capacity to differentiate. Fetal RPE cells were plated at 4,000 cells/cm2 and passaged at
subconfluence every 3–5 days. At each passage a portion of the cells were plated at 80,000 cells/cm2 and maintained without further passaging.
a Whole culture photographs of 64-day serially passaged RPE cells from three different donors (A, B, and C) plated on microporous inserts at
80,000 cells/cm2. b Phase contrast micrographs of 3-day low density cultures of P0 (a) and P5 (c) cells plated at low density reveal only minor
differences in phenotype. At 32 days P0 cultures (b) plated at high density have a prototypical pigmented cobblestone RPE phenotype, while P5
cells (d) are not pigmented and have a disorganized morphology. c Passage 0 cells were plated at 4,000 and 80,000 cells/cm2 on tissue culture
plastic and maintained without further passage. Phase contrast (Ph) and brightfield (Bf) micrographs of the cultures as function of time show that
high density plating is a requirement for normal RPE differentiation
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sion might account for the switch to a persistent mesen-
chymal phenotype, the different cluster groups were
subjected to gene ontology enrichment analysis [23, 24].
Consistent with current understanding of the RPE
phenotype, Group a, which is comprised of genes most
highly expressed in terminally differentiating RPE, is
enriched for genes previously identified as RPE marker
genes [25, 26] or with functions consistent with the dif-
ferentiated RPE phenotype. Among the most regulated
genes in this group are the pigmentation related genes
TYR, TYRP1, DCT, and OCA2; TRPM1 and TRPM3
which harbor the RPE microRNAs MIR204 and MIR211
in their intronic regions [31]; and genes associated with
the visual cycle (LRAT, RPE65, RPLBP1, RDH5, and
RBP1). Conversely, Groups d and e, which consists of
genes whose levels are most abundant in dedifferentiated
RPE, are enriched for genes commonly associated with a
mesenchymal phenotype or wound response such as
ACTA2, CDH2, CTGF, FN1, TGFB1, and TGFB2. While
Group f, is not statistically enriched for RPE signature
genes, many of the genes in this group are critical for
important RPE functions or development (PMEL, AQP1,
STRA6, BMP7).Identification of a core set of genes associated with the
potential to acquire a RPE phenotype
To gain further understanding into the molecular basis
underlying the switch to a persistent mesenchymal state,
attention was directed towards the subconfluent cells. Un-
like the case with confluent P0 and P5 cells where there
are enormous changes in gene expression and virtually
every regulatory pathway of potential interest is impacted,
only 565 genes are differentially expressed between sub-
confluent P0 and P5 cells. Approximately half of these
transcripts are more abundant in P5 cells. Given that it is
determined that the P0 cells will become RPE and the P5
cells will become mesenchymal, it follows that the key dif-
ferences that dictate their final phenotype might lie in this
relatively small set of genes. Gene ontology enrichment
analysis of this gene subset demonstrates that it is highly
enriched for genes associated with the cell cycle (n = 53,
P value <10−7) and genes often associated with wound re-
sponses (extracellular matrix: n = 49, P value <10−18; cell
adhesion: n = 50, P value <10−7; growth factor binding:
n = 15, P value <10−5; actin binding: n = 26, P value <10−5;
positive regulation of apoptosis: n = 29, P value <10−3).
To help determine how the products of this core set of
differentially expressed genes might act to control the
Fig. 2 Genome-wide transcriptome profiling and cluster analysis uncovers functionally related groups of genes that are co-regulated as a function
of passage and time. Genes with a two-fold or greater change in gene expression as a function of passage or time were segregated based on
their expression profiles using AutoSOME 2.1. Individual clusters with similar expression profiles were placed in major expression groups (a-g)
following manual examination. The headers of each group are representative of gene ontology classes that are over-represented in each group.
The value associated with the ontology groups is the enrichment P value. The color scale indicates the expression level as a percentage of the
maximum value for that gene. Each column represents a unique biological replicate (n = 3). Rows represent unique genes. The corresponding
gene identifiers and associated data can be found in Additional file 3: Table S2
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As shown in Fig. 3, nearly one-third of the products of
this core gene set could be organized into a network
based on direct protein-protein interactions or being
part of a common curated pathway. Moreover, this 158-
node interactome could be segregated into two modules;
one that is involved in the cell cycle and one that is
enriched for proteins commonly associated with wound
responses. In general, the cell cycle transcripts are found
at higher levels in minimally passaged RPE and the
wound response transcripts are more abundant in highly
passaged RPE.
Interestingly, within the wound response module, over
70 % of the proteins are found in the extracellular com-
partment, consistent with a possible role in autocrine/
paracrine signaling. Most notable in the wound response
module are a group of highly interconnected nodes fo-
cused around the TGFβ family ligands TGFB1, TGFB2,and INHBA. Additional groups of potential interest are
chemokines and chemokine receptors (CXCL1, CXCL12,
CXCL14, CXCR4, CXCR7), WNT signaling (FZD7, SFRP1,
WNT2B, WNT5B), regulators of angiogenesis (ANGPT1,
ANGPTL4, VEGFA), insulin growth factor binding proteins
(IGFBP3, IGFBP7), and G-protein coupled receptors and li-
gands (EDNR, LPAR1, SSTR1 and EDN1, GAL, NMU,
NTS, PMCH). Gene products of note in the mitosis mod-
ule are CCND2 and the cyclin-dependent kinase inhibitors
CDKN1C, CDKN2A, and CDKN2B. Many of the
remaining gene products in the cell cycle module are com-
ponents of the replication machinery.
Preservation and restoration of the RPE phenotype by
wound response inhibitors and stimulation of mitosis
Based on the results of the transcriptome analysis we hy-
pothesized that the negative effects of subconfluent cul-
ture on RPE differentiation might be prevented or
Fig. 3 Differential expression of a core set of genes whose products comprise a functional interactome is an underlying feature of chronically
wounded RPE cells. The 565 genes with two-fold or greater differences in expression between 3-day P0 and P5 cultures were analyzed using
STRING 9.1 to identify genes whose products have experimentally determined protein-protein interactions (Experimental) or are part of a
common curated pathway (Knowledge) and the resulting interactome was rendered using Cytoscape 3.0.2. The interactome is segregated into
two sub-modules, one enriched for gene products involved in the cell cycle and the other for genes that are often associated with the response
to wound stimuli. The line color indicates the nature of the connection with direct protein-protein interactions taking precedence over common
pathway. The gene node color represents the log2 transformed P5:P0 gene expression ratio as determined by microarray analysis
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response signaling pathways or FGF2 to stimulate cell
division. As an initial test, P0 cells were plated at low
density to inhibit terminal RPE differentiation, and
maintained in medium supplemented with A-83-01,
thiazovivin, LDN-193189, XAV939, or FGF2 for 32 days.
A-83-01 blocks the ligand activated kinase activity of the
type I TGFβ receptors ACVR1B, TGFBR1, and ACVR1C
[32]. These receptor subunits, which are considered to
be members of the TGFβ receptor subfamily, are also re-
ferred to as activin-like receptors (ALK) 4, 5, and 7. Li-
gands that have been reported to activate these receptor
kinases include INHBA, INHBB, GDF11, TGFB1, and
TGFB2 [33]. Based on the transcriptome analysis, only
ACVR1B and TGFBR1 are expressed in differentiated or
non-differentiated RPE cells. Thiazovivin is an inhibitor
of the rho-associated, coiled-coil-containing protein ki-
nases, ROCK1 and ROCK2 [34]. ROCK1 and ROCK2
regulate the actin cytoskeleton and participate in a num-
ber of relevant pathways including cadherin, chemokine,
focal adhesion, WNT, and TGFβ signaling [35]. LDN-
193189 is an inhibitor of the BMP subfamily of the
TGFβ type I receptors [36, 37]. Members of this familywith detectable microarray signals in RPE are ACVR1
(ALK2), BMPR1A (ALK3), and BMPR1B (ALK6). Among
the ligands that activate these receptors are BMP2, BMP4,
BMP7, GDF5, GDF6, INHBA, and INHBB [33]. XAV939
is an antagonist of WNT signaling that acts indirectly to
increase the level of axin, a key protein involved in the
degradation of β-catenin [38]. Basic FGF (FGF2) is a
widely recognized mitogen that has been previously shown
to stimulate RPE cell division [39, 40].
As shown in Fig. 4a, all of the inhibitors and FGF2 have
the capacity to improve the morphology of low density P0
RPE cultures, albeit to varying extent. The WNT signaling
inhibitor, XAV939, and the BMP subfamily receptor in-
hibitor, LDN-193189, are the least effective. XAV939
treated cells have a more regular, somewhat epithelial-like
morphology when compared to untreated control cells,
however there is no evidence of pigmentation. LDN-
193189 treatment has minimal effect on gross morph-
ology, but there is improved pigmentation with foci of
sparse pigmentation being evident throughout the culture.
In contrast, inhibition of TGFβ subfamily receptor and
ROCK activity using A-83-01 or thiazovivin, as well as
treatment with the mitogen FGF2 are strikingly more
Fig. 4 FGF2 or small molecule inhibitors of wound response promote differentiation at low plating density. Passage 0 cells were plated at 4,000
cells/cm2 and grown in the presence of 500 nM A-83-01, 2 ng/mL FGF2, 500 nM thiazovivin, 200 nM LDN-193189, or 5 μM XAV939. The vehicle
(DMSO) alone served as the control. a Whole culture images (above), phase contrast (Ph) and brightfield micrographs (Bf) taken at day 32
demonstrate that A-83-01, FGF2, and thiazovivin treated cultures maintain the capacity to differentiate after low density plating. b Whole
transcriptome profiles of the 32-day treated and control low density P0 cultures were determined and compared to the expression profiles of
differentiated 32-day high density P0 cultures. The transcriptome profiles of 32-day differentiated (P0) and undifferentiated (P5) RPE cells plated
at 80,000 cells/cm2 from three donors are shown for comparison. Only genes with two-fold or greater P0:P5 expression ratios and a P0 or P5 net
intensity ≥15 were evaluated. The color scale indicates the log2 transformed expression level relative to the mean value of the 32-day high
density P0 cells. Black indicates identity. The values on the right indicate the Pearson’s product–moment correlation coefficient (PC) for all
expressed genes relative to the mean of the high density P0 profiles
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are quantitative differences, A-83-01, thiazovivin, and
FGF2 treated cultures all have substantial regions of pig-
mentation and prototypical RPE morphology. Further-
more, when cells are plated at sufficient density to allow
for differentiation in control medium, both A-83-01 and
thiazovivin treatment result in more uniform phenotype
(Additional file 2: Figure S2). No negative effects of
LDN-193189 on gross morphology were apparent in
high density cultures. On the other hand, XAV939
treated high density cultures had reduced levels of pig-
mentation and an apparent increase in cell size relative
to control cultures.
In addition to assessing the effects of these agents on
gross morphological criteria, their effects on global gene
expression were evaluated (Fig. 4b). In general, the ef-
fects of the treatments on gene expression mirrored that
observed with respect to morphology and pigmentation.
Cells treated with A-83-01, FGF2, and thiazovivin have
transcriptome profiles most similar to high density P0
cultures. Interestingly, A-83-01 treatment results in a
significant number of RPE marker genes with elevated ex-
pression (Fisher’s exact test, P value <0.001) and genes as-
sociated with P5 cells with reduced expression (Fisher’sexact test, P value <10−5) relative to untreated P0 cells;
suggesting that there may be some degree of active TGFβ
signaling in P0 cells.
With the finding that inhibition of TGFβ receptor
signaling supported RPE differentiation at low plating
density, further investigations were directed at assessing
if A-83-01 could prevent the loss of, or even rescue the
RPE phenotype after repeated passage (Fig. 5). To deter-
mine if TGFβ pathway inhibition would block the loss of
phenotype, cells were passaged at subconfluence in the
presence of A-83-01. To ascertain whether RPE cells
could be passaged in normal medium and subsequently
rescued by A-83-01, cells were passaged in normal
medium and at each passage a portion of the culture
was seeded at high density in medium containing A-83-
01. Based on the degree of pigmentation, cells cultured
in the continual presence of A-83-01 continue to differ-
entiate for at least five passages; four passages beyond
that observed in the absence of A-83-01. The ability of
A-83-01 to rescue the cells was even more pronounced.
Cells grown in normal medium and subsequently treated
with A-83-01 had substantial levels of pigmentation even
after seven preceding passages in control medium. Con-
sistent with the results obtained at low density plating
Fig. 5 Inhibition of TGFBR1/ACVR1 signaling extends the effective lifespan of RPE cells. Cells were serially passaged using medium supplemented
with 500 nM A-83-01 or normal medium. At each passage, parallel cultures were established using a plating density of 80,000 cells/cm2 and
maintained for 32 days in the medium used for passage. To determine whether A-83-01 could restore the capacity to differentiate after passage
in control medium, cells passaged in control medium were also plated into medium supplemented with 500 nM A-83-01. a Whole culture
photographs of the high density cultures taken after 32 days (A-83-01, cells passaged and maintained in A-83-01; Control, cells passaged and
maintained in normal medium; Control to A-83-01, cells passaged in normal medium and switched to A-83-01 at the indicated passage). See Additional
file 2: Figure S3 for phase contrast and brightfield micrographs. b Analysis of RNA expression of select markers of RPE differentiation (blue gene symbols)
and RPE wound response (yellow gene symbols) using RT-qPCR. The color scale indicates the expression level relative to the maximum value for that
gene. The expression level for the maximum value relative to the housekeeping genes is listed to the right of the heatmap (Amount)
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the prototypical epithelial morphology in this experimen-
tal paradigm (Additional file 2: Figure S3). In addition to
its effects on gross morphology, immunological and cyto-
logical examination reveals that A-83-01 suppresses the
expression of smooth muscle actin (ACTA2), preserves
the prototypical cortical actin cytoskeleton and co-
localization of tight junction protein 1, and maintains the
expression and localization of the RPE marker proteins,
PMEL and BEST1 (Additional file 2: Figure S4). While the
beneficial effects of inhibition of TGFBR1 and ACVR1 sig-
naling are readily apparent, it should be noted that the ef-
fects are not limitless. Eventually the cells fail to
differentiate, suggesting there may be more to the loss of
capacity to differentiate with increasing passage than
TGFβ-mediated mesenchymal transition alone.
The effect of A-83-01 on the expression of a set of
representative passage-dependent genes was evaluatedusing RT-qPCR (Fig. 5b and Additional file 2: Figure S5).
In general, A-83-01 treatment promoted the expression of
genes that are preferentially expressed in differentiated
RPE (RPE genes) and suppressed the expression of genes
that are most highly expressed in non-differentiated RPE
(Wound Response genes). The one exception was SMOC2,
which is normally expressed in differentiated P0 and P1
cells maintained in control medium. Not only is the ex-
pression of SMOC2 not maintained by A-83-01, it is
inhibited by A-83-01. As was seen in the low density plat-
ing paradigm (see Fig. 4), P0 cells treated with A-83-01
and plated at high density have higher than normal levels
of some RPE transcripts (LIN7A, LPL, OTX2 and RAX)
and lower than normal levels of some Wound Response
transcripts (COL1A1, COL1A2, GDF6, ITGA11, TGFBI)
(Additional file 2: Figure S6).
While in general A-83-01 promotes the expression of
RPE marker genes and suppresses the expression of
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of expression that are not always in direct relationship
with the gross phenotype (Additional file 2: Figure S5).
For example, in the case of the RPE genes, the level of
CDH3, CLIC6 and TYRP1 transcripts remain relatively
constant in the presence of A-83-01 at all passages.
Whereas, LIN7A, LPL, LRAT and SOX10 levels decrease
significantly with passage, even in the presence of A-83-
01. In the case of the genes that are most highly expressed
in non-differentiated RPE and are suppressed by A-83-01,
three genes (LUM, CDH11, and ZBED2) have evident in-
creases in expression at the later passages when there is a
notable loss of capacity to terminally differentiate; while
the expression of the remaining wound response genes
remained blocked by A-83-01. Some genes (OTX2, RAX,
CDKN2B, COL1A1, and COL1A2) even have apparent
cyclical expression profiles as a function of passage.
As a broader assessment of the efficacy of A-83-01 to
rescue the RPE phenotype, we also carried out a com-
parative RNA-Seq based transcriptome analysis of differ-
entiated P0 RPE, mesenchymal P4 cells, and A-83-01
rescued P4 cells. Consistent with the microarray analysis,
4,590 genes were found to be differentially expressed
(FDR ≤0.01) between 32 day old differentiated P0 and
untreated P4 cells cultures with the genes being split
roughly equally between being upregulated or downreg-
ulated. Seventy-five percent of the genes found to be dif-
ferentially expressed using RNA-Seq were also identified
by microarray analysis. When the expression level of
these passage-dependent genes were evaluated in cells
that had been passaged four times in normal medium
and then treated with A-83-01, 87 % had at least a 25 %
recovery in expression relative to P0 cells (Fig. 6a). Over
75 % of the passage-dependent genes had a recovery of
50 % or better following A-83-01 treatment. As highlighted
in Fig. 6b, genes whose expression is enhanced by A-83-01
include those with well know roles in key RPE functions
such as adhesion (CHD1, CLDN19, C1QTNF5, ITGB8), ion
transport (BEST1, TRPM1, TRPM3), rod outer segment
phagocytosis (MERTK, MYO7A), pigmentation (DCT,
OCA2, PMEL, TYR, TYRP1), retinoid metabolism (RBP7,
RDH5, RLBP1, RPE65), pigment epithelial growth factor
(SERPINF1), and RPE gene regulation (EYA2, LHX2,
MITF). As would be predicted, A-83-01 treatment downre-
gulates the expression of well recognized markers or regu-
lators of EMT and TGFβ signaling to levels similar to or
below that seen in differentiated P0 RPE.
Finally, to address whether the effects of A-83-01 on
RPE phenotype were specific to inhibition of the TGFβ
pathway, dose–response analyses of A-83-01 and two
additional TGFBR1/ACVR1B inhibitors, RepSox [41–43]
and SB-431542 [44, 45], were performed (Additional file
2: Figure S7). A-83-01, RepSox, and SB-431542 all pro-
moted RPE differentiation and gene expression, andblocked the expression of wound response genes in a
typical dose-responsive manner. Moreover, based on the
subset of genes examined by quantitative PCR, treat-
ment with RepSox resulted in an expression profile most
similar to that of differentiated P0 cells. Like A-83-01,
both RepSox and SB-431542 can increase the number of
passages over which RPE can differentiate and reverse
the effects of passage (data not shown).
Altered gene expression of TGFβ pathway components
To gain further insight into how changes in gene expres-
sion might account for the loss of capacity to differentiate,
known participants in TGFβ signaling with passage-
dependent changes in expression were identified. Of the
114 TGFβ signaling genes with detectable expression ex-
amined, 53 had two-fold or greater differences in expres-
sion between P0 and P5 cells (one-way ANOVA P value
≤0.05) in at least one of the four measured time points
(Fig. 7). Taking into consideration that A-83-01 inhibits
signaling via TGFBR1 and ACVR1B, the pattern and ex-
tent of changes in expression, and their documented func-
tion, two groups of genes of interest were identified. The
first group is comprised of the ligands INHBA, INHBB,
TGFB1, and TGFB2. These ligands all signal via the ap-
propriate receptors and are found at elevated levels in
both subconfluent and confluent late-passage cells. The
second group is comprised of genes coding for proteins
that regulate the activity and/or availability of TGFβ li-
gands. Within that group, THBS1, CTGF, and DCN are
of most interest. All three of these genes are found at
substantially higher levels in subconfluent and confluent P5
cells, and the products of these genes promote the activity
of TGFB1 and TGFB2. Thrombospondin-1 is capable of
directly activating latent TGFβs by disrupting the inter-
action with the latent TGFβ binding proteins [46–48].
CTGF directly binds both TGFβs and THSB1, which then
results in enhanced signaling through an ill-defined mech-
anism [49, 50]. Although DCN is most often associated
with inhibition of TGFβ signaling [51], this is not always
the case. In proliferating myoblasts DCN promotes the ac-
tion of TGFβs [52–55]. One other ligand of note is GDF6.
Its expression is almost exclusive to P5 cells and as such it
is a prime candidate for participating in the prevention of
RPE differentiation. Of note, the levels of expression of
these regulators of the TGFβ pathway in passaged RPE
treated with A-83-01 are the same or lower than that of
differentiated P0 RPE (see Figs. 5 and 6).
Altered expression of RPE wound response genes in AMD
Consistent with a role of wound response in the pro-
gression of AMD, we have previously shown that AMD
is associated with elevated levels of TGFB2 mRNA in
both the RPE-choroid and retina [14]. To further evalu-
ate the role of wound response in AMD we compared
Fig. 6 A-83-01 treatment largely restores the RPE transcriptome. Untreated P0 cells, untreated P4 and P4 cells treated with 500 nM A-83-01 were
seeded at 80,000 cells/cm2. After 32 days the cells were harvested and their transcriptome profiles were determined using RNA-Seq. a Heatmap
showing the expression levels relative to the mean of the three P0 cultures. Only the 4,590 genes with significant (FDR ≤0.01) expression differences
between P0 and untreated P4 cells are depicted. The values on the right indicate the Pearson’s product–moment correlation coefficient (PC) for all
expressed genes relative to the mean of the high density P0 profiles. b Relative expression levels of select genes with well-known roles in RPE-specific
functions or EMT and wound response. For each gene, the expression levels are normalized relative to the maximum value (mean +/− SEM, n = 3)
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our list of early AMD, CNV, and GA candidate genes.
Only genes expressed by cultured RPE cells were consid-
ered, and for a match to be recorded the direction of
change had to be consistent with the hypothesis that
wound response is a component of AMD. As highlighted
in Fig. 8, there is a highly significant enrichment of
genes that change as a function of passage in CNV and
GA, in both the RPE-choroid and retina. In the RPE-
choroid, the enrichments were seen in both the macular
and the extramacular regions, for both the upregulated
and downregulated genes. In the retina, the overlap was
largely limited to the macula and was only observed
among the genes with increased expression in AMD and
passaged RPE. The lack of enrichment with the down-
regulated class in the retina is expected as most of the
genes with decreased expression in the cell culture
model are associated with RPE-specific function. Con-
sistent with the lack of overlap between genes that
change in early AMD and passage, we found no signifi-
cant overlap with the sets of AMD genes reported by
Whitmore et al. [56] or Hunter et al. [57] whose analysis
was limited to early AMD or AMD in general.
Altered expression of AMD-associated genes as a function
of prolonged wound stimulus
In addition to evaluating the overlap between genes with
expression changes in the wound response model and inAMD, genes that have been identified as risk factors in
AMD were evaluated. Fig. 9 shows the expression data for
a number of AMD-risk genes with two-fold or greater dif-
ferences as a function of passage. In large part, the analysis
focused on genes whose association has been corroborated
in multiple studies or large cohort genome-wide associ-
ation studies [58–97].
The majority of AMD genetic risk is attributed to vari-
ants of several components of the complement cascade;
of which CFH, CFB, CFI, C2, and C3 are differentially
expressed in the wound response model. However, the
net effect of the observed changes on complement activ-
ity is unclear. The reduced expression of CFH in sub-
confluent early-passage cells (3 days, P0) and reduced
expression of CFI in late-passage confluent cells (16–64
days, P5) cells should act to promote complement activ-
ity, whereas decreased expression of CFB, C2, and C3
should lead to a lowered complement response. Expres-
sion of the copy number variant associated complement
genes, CFHR1 and CFHR3 was not detected in any RPE cell
culture. Expression of HTRA1, which is located at the other
major AMD loci, is also substantially altered with four-fold
higher levels being found in confluent late-passage RPE.
Consistent with the potential role of wound response in ad-
vanced AMD, experimentally induced HTRA1 expression
in RPE results in altered Brüch’s membrane structure, poly-
poidal choroidal vasculopathy, and degeneration of the RPE
and photoreceptors in mouse models [98, 99]. However,
Fig. 7 Sustained subconfluent culture results in widespread changes
in the expression of genes involved in TGFβ signaling. One hundred
and fourteen genes whose products are involved in TGFβ signaling were
identified following a survey of curated pathways and the literature.
Shown are those genes with a two-fold or greater difference in expression
as a function of passage and a P value ≤0.05 (one-way ANOVA, n = 3) at
any of the four time points, as determined by microarray analysis. The
length of each bar indicates the level of expression relative to the
maximum expression value for that gene. The axis of the P0 (blue) and
P5 (red) bars are inverted to allow for ease of comparison
Fig. 8 Genes associated with the RPE wound response are
over-represented among those genes with altered expression in
advanced AMD. Genes with two-fold increased or decreased
expression as a function of passage were cross-referenced with the
Up- and Down- RPE-choroid and retina AMD-associated gene sets
reported by Newman et al. [14]. The charts depict the significance
(−log(P value), Fishers’s exact test) of the overlap relative to the
null hypothesis for the RPE-choroid (a) and retina (b) gene sets.
Combined refers to the gene set resulting from the pooled analysis
of the macular and extramacular samples
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TGFβ mediated wound response is unclear as HTRA1 has
also been shown to inhibit TGFβ signaling through prote-
olysis of the ligands and receptors [100–103]. The expres-
sion profile of ARMS2, which is in linkage disequilibrium
with HTRA1, could not be evaluated due to lack of repre-
sentation on the microarray.
In the context of TGFβ mediated wound responses, the
AMD-associated genes TGFBR1 and GDF6 are most in-
teresting. TGFBR1, whose expression increases post-
confluence as a function of passage, is a target of A-83-01
and primary transducer of TGFB1 and TGFB2 activity.GDF6 is nearly exclusive to P5 RPE cells and as such it is
a candidate ligand for mediating the irreversible switch in
phenotype following sustained wound stimulus. Although
GDF6 is essential for normal eye development and de-
creased GDF6 expression or function can result in ocular
defects, microphthalmia, or anaophthalmia [104], its post-
development roles are uncertain and there is precedence
for TGFβ ligands having opposite effects in the regulation
of development and stasis. For example, activin A (an
INHBA dimer), promotes the differentiation of the RPE
during development and from stem cells [105, 106] and
also promotes wound responses in the adult [107]. Pro-
motion of angiogenesis is a well-known component of
wound response and the role of VEGFA, both functionally
and genetically in AMD is well established. VEGFA ex-
pression is substantially reduced in subconfluent RPE and
in confluent P5 RPE relative to differentiated RPE. Al-
though this seems contradictory with the fact that neovas-
cularization is a defining feature of CNV, it has been
Fig. 9 AMD risk-associated genes with altered expression in late-passage
RPE. Of 63 genes with reported association with altered risk for AMD that
were evaluated, 50 were found to be expressed by cultured RPE. Of the
expressed genes 75 % were found to have two-fold or greater changes
in expression as a function of passage based on the microarray analysis
(one-way ANOVA P value ≤0.05, n = 3). Shown are the log2 transformed
P5:P0 expression ratios for genes whose association has been replicated
in multiple studies or identified in recent large cohort genome wide
association or single loci analysis. The corresponding citations (Ref.) are
indicated on the right
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the margins surrounding the neovascular lesion [108]. A
similar reduction in the choriocapillaris was also observed
in GA. Both FILIP1L and TNFRSF10A are reported to be
involved in promoting apoptosis. Consistent with this
function, along with the increased cell death observed in
highly passaged RPE and in GA, the expression of FILIP1L
and TNFRSF10A is more than four times higher in conflu-
ent P5 RPE cells. Finally, there are a number of genes in-
volved in lipid metabolism with genetic variants associatedto AMD, including LPL, SCARB1, APOE, FADS1, FADS2,
and LRP6. All of these genes are expressed at significantly
lower levels in highly passaged RPE. There was no evidence
of expression of two other lipid related AMD genes, LIPC
and CETP, under any condition.
Discussion
In this study we investigated the molecular basis of in-
trinsic RPE wound repair, how extended periods of
wound stimulus lead to a chronic state of wound re-
sponse that is independent of further stimulus, and how
these processes might relate to the progression of AMD.
Using a cell culture model system that views disruption of
cell monolayers during routine passage as a wound stimu-
lus, we showed that when repeatedly passaged RPE reach
confluence they fail to achieve a normal cell density, they
fail to inactivate genes associated with successful wound
repair, they fail to reactivate genes associated with termin-
ally differentiated RPE, and they aberrantly upregulate
genes that are unique to a terminal mesenchymal pheno-
type. With respect to identifying the mechanisms that ac-
count for the change in behavior, we identified a core set of
genes with altered expression in subconfluent, repeatedly
passaged cells. An analysis of this subset of genes revealed
that they can be organized into an interactome comprised
of two modules; one consisting primarily of genes involved
in cell division and the other containing genes often associ-
ated with wound response, development, or stasis. As a
rule, the directions of the changes in expression are con-
sistent with a passage-dependent decrease in mitosis and
activation of a wound repair program.
Using pharmacological experiments, we found that
stimulation of mitosis using FGF2 or repression of
wound responses using TGFBR1/ACVR1B kinase or
Rho-associated, coiled-coil containing kinase inhibitors
all promoted RPE differentiation at plating densities
lower than normally required for the establishment of
the RPE phenotype. In addition, when RPE cells were
passaged in the presence of the TGFβ receptor inhibitor,
A-83-01, there was a substantial increase in the number
of times cells could be passaged and retain the capacity
to acquire a pigmented epithelial morphology. More
strikingly, when cells were passaged in normal medium
and subsequently treated with A-83-01, they regained
the capacity to regenerate the characteristic pigmented
epithelial morphology. In addition, the finding that sus-
tained inhibition of TGFβ signaling does not prevent
normal RPE differentiation demonstrates that TGFβ sig-
naling is not essential for RPE differentiation or pro-
ductive RPE wound repair.
A major objective of this study was to identify the
regulatory mechanisms that account for the change in
terminal phenotype following protracted subconfluent
culture. In that regard, a link between decreased rates of
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phenotype is not inherently apparent. Both early- and
late-passage cells achieve confluence and the cell density
at the point of confluence appears roughly equivalent. A
potentially significant growth-related difference is that
differentiation-competent cells attain a higher final cell
density; the implication being that they continue to div-
ide for a period of time post-confluence. The passage
dependent changes in the expression of multiple cyclin-
dependent kinase inhibitors may be important in this re-
spect. Most notable, are CDKN2A and CDKN2B which
are expressed at substantially higher levels in late-passage
cells and CDKN1C which is preferentially expressed in
early-passage cells. TGFβ induced increases in CDKN2B
have been linked to decreased cell proliferation in multiple
cell types, including RPE [109–111]. No passage dependent
differences in the expression of FGF family ligands or re-
ceptors in subconfluent cells were observed, suggesting
that changes in FGF signaling are not responsible for the
changes in phenotype. It is possible, that continuation of
cell division post-confluence may be essential for establish-
ing an ordered epithelial monolayer, establishment of
apical-basal polarity, and the subsequent induction of RPE
specific gene expression.
ROCK is best known for its role in regulation of the
actin cytoskeleton, but it has many additional targets and
has been linked to multiple functions including cell motil-
ity, establishment of cell polarity, cell proliferation, and
cell death [112–114]. ROCK1 and ROCK2 participate in
multiple pathways including the TGFβ, WNT, cadherin,
and integrin pathways. Moreover, inhibition of ROCK sig-
naling has been shown to mitigate experimentally induced
EMT in a number cell types as well as RPE [115–121].
Given the widespread involvement of ROCK in EMT it is
not unexpected that inhibition of ROCK would aid in the
preservation of the RPE phenotype. However, due to
ROCK’s promiscuous involvement in several pathways lit-
tle certainty is gained regarding the regulatory signals that
lead to an epithelial-to-mesenchymal switch. Despite this
lack of mechanistic clarity, it is worth noting that we have
shown that the ROCK inhibitor Y-27632 also extends the
number of passages that stem cell derived RPE can
undergo and maintain their normal phenotype and func-
tion [122]. We have observed similar effects of ROCK in-
hibition on preventing the passage-dependent loss of RPE
phenotype using fetal RPE and thiazovivin, although the
effect may be less efficacious than TGFBR1/ACRV1B in-
hibition with respect to reversal of the effects of passage
or low density plating (M. Radeke and R. Croze, unpub-
lished observations).
The role of altered TGFβ family signaling in the
passage-dependent switch to a mesenchymal phenotype
is clearly demonstrated by the ability of the TGFBR1/
ACVR1B kinase inhibitors to block and reverse thisphenomenon. The TGFβ superfamily is comprised of
over 30 different ligands; TGFβs, activins and inhibins,
bone morphogenesis proteins (BMP), growth differenti-
ation factors (GDF), and nodal. While the ligands can be
categorized based on sequence homology, they may be
best segregated based on whether they signal via receptors
that employ SMAD2/3 or SMAD1/5/8 in their signal
transduction pathways. Because TGFβs predominantly
utilize SMAD2/3 and BMPs generally act via SMAD1/5/8
these homologous pathways are often referred to as the
TGFβ and BMP pathways. Depending on context, activins
and some GDFs can use either or both pathways. The
TGFβ pathway is often assigned to directing mesenchymal
differentiation and maintenance of pluripotency, while the
BMP pathway is ascribed to promoting the differentiation
of various cell types. In addition to the canonical SMAD-
dependent pathway, signaling can occur through the en-
listment of multiple non-canonical pathways employing
RHOA/ROCK, TAB1/TAK1, PI3K, PP2A, or RAS [123].
Analysis of the passage-dependent changes in expres-
sion of 114 genes associated with the TGFβ and BMP
pathways revealed that over half of the genes had signifi-
cant passage-dependent changes in expression of two-
fold or greater. However when the analysis is limited to
those genes with altered expression in subconfluent
cells, only the ligands TGFB1,TGFB2, INHBA, INHBB,
and GDF6 and the ligand interactors THBS1, CTGF, and
DCN stand out after considering the direction of change
and possible mode of action. The synthesis of TGFβ by
RPE and its enhanced production following wounding
[124–126], as well as its effect on proliferation and pro-
motion of mesenchymal phenotypic changes in RPE [39,
127–129] have been recognized for some time. Similarly,
INHBA has been shown to be expressed by RPE and,
like TGFβ it inhibits RPE proliferation [130]. It is tempt-
ing to speculate whether these differences in expression
of the TGFβ and activin ligands account for the marked
change in behavior following sustained subconfluent cul-
ture. It is not clear, however, that these changes in gene
expression are sufficient to cause the marked change in
post-confluence phenotype, since both minimally and
highly passage cells express significant levels of these
genes prior to establishing a confluent monolayer. From
this perspective the expression profile of GDF6 is intri-
guing. There is little to no expression in early-passage
cells and there is more than a ten-fold increase in highly
passaged cells irrespective of state of confluence. While
current knowledge on GDF6 is limited, there is evidence
suggesting a possible role in EMT. GDF6 can promote
differentiation of cells of mesenchymal origin, and it
can bind to the type 2 receptor, ACVR2B, with high af-
finity [131–133]. ACVR2B is known to associate with
ACVR1B (ALK4), an activator of SMAD2/3 [134].
Whether GDF6 can signal through ACRV1B is uncertain
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been studied does not express ACRV1B and in vitro ana-
lysis has failed to detect ACRV1B binding. Based on our
analysis, cultured RPE cells have substantial levels of
ACRV1B expression, irrespective of passage or time.
Assuming that the changes in gene expression result
in increased protein expression, it is possible that the li-
gands may not be available in a biologically active form.
Both INHBA and INHBB are inhibited by follistatin
(FST) [135], which is also expressed at elevated levels in
late-passage cells. TGFB1 and TGFB2 are secreted as la-
tent complexes with the TGFβ binding proteins, LTBP1
and LTBP2 [136, 137], whose expression also increases
with passage. In this context the elevated expression of
THBS1, CTGF, and DCN are most interesting. In
addition to their role in latent TGFβ activation or po-
tentiation, it has been shown that THBS1 treatment of
RPE leads to TGFB1 activation [138] and CTGF treatment
of RPE stimulates migration and increases the expression
of cellular fibronectin, a marker of EMT [139, 140]. Like
GDF6, DCN is highly upregulated in both subconfluent
and confluent late-passage cells and there is little to no ex-
pression in early-passage cells. In addition to promoting
the action of TGFβs in proliferating myoblasts [52–55],
DCN can cause increased expression and secretion of
THSB1 [141, 142]. Taken together, the passage-dependent
increase in expression of multiple TGFβ ligands and en-
hancers of TGFβ signaling could provide a potent mech-
anism for sustained activation of the TGFβ pathway.
While TGFβ mediated-EMT plays a dominant role in
the loss of RPE phenotype with increasing passage, our re-
sults suggest that there are other passage-dependent pro-
cesses that contribute to loss of capacity to differentiate.
Even in the presence of sustained repression of mesenchy-
mal gene expression by A-83-01, there is a steady decrease
in a subset of RPE-specific genes and an eventual loss of
RPE phenotype with extensive passage. The identity of
these other processes remains unknown. Clues as to their
identity might be found in the small subset of passage-
dependent genes that do not respond to TGFβ pathway
inhibition, although that will likely require determin-
ation of the optimal small molecule inhibitor, doses, and
treatment schedules in order to minimize confounding
effects due to off-target drug effects. The ultimate loss
of phenotype appears not to be related to terminal sen-
escence as P7 cells are still mitotic and largely negative
(>85 %) for senescence-associated β-galactosidase (un-
published observations).
Consistent with the hypothesis that the transition from
early AMD to advanced AMD is associated with the onset
of a dysregulated RPE wound response, we found an over-
representation of genes whose expression changes after
prolonged subconfluent culture among the genes with dif-
ferential expression in CNV and GA RPE-choroid andretina. In the RPE-choroid there was evidence of wound
response in both macular and extramacular regions,
whereas in the retina the region of response was limited to
the macula, as is the primary visual loss. In the CNV RPE-
choroid more than 35 % of the overlapping genes are over-
expressed in subconfluent late-passage RPE cells. Among
this list are TGFB2, CTGF, DCN, LTBP1, and CDKN2A; as
well as SPP1, the most highly overexpressed gene in 3-day
late-passage cells. SPP1, is known to be upregulated by
TGFβ in bone cells and it is essential for TGFB1 induced
cardiac myofibroblast differentiation [143–145]. This dif-
fers with the situation in GA where less than 20 % of the
overlapping genes are overexpressed in subconfluent late-
passage cells. Moreover, there is essentially no representa-
tion of the TGFβ pathway genes in the RPE-choroid GA
data set. This difference might reflect the fact that in CNV
a majority of the cells in the neovascular lesions are
TGFβ-immunoreactive RPE and fibroblast-like cells of
possible RPE origin [146, 147]. In contrast, in GA the dis-
ease state is best defined by cell death, with the actively in-
volved cells possibly being limited to the margins of the
disease area. In the retina the one differentially expressed
gene of note in the context of this study is TGFB2, which
is overexpressed in both CNV and GA. This evidence of
the association of a RPE wound response in advanced
AMD, coupled with prior reports of elevated TGFβ ex-
pression in AMD and linkage of a TGFBR1 polymorphism
with AMD risk all point to dysregulation of TGFβ signal-
ing as a contributing factor in AMD progression.
Finally, when contrasting a culture based system with
in vivo disease one must keep in mind the differences
between the two cases. In the tissue culture model there
is a single cell type and a clearly defined stimulus.
Whereas in the disease, there are multiple cell types and
processes that contribute to the disease and can muddy
analysis. In addition, there are aspects of the model sys-
tem that may not truly reflect the disease state or
process. Some of these differences may account for the
lack of evidence of wound responses in early AMD.
Also, in the early stages of AMD the affected areas are
minimal with respect to the tissue as a whole and vari-
able between donors; the net result being a dilution of
signals and increased noise due to inter-patient variabil-
ity. Determining the extent to which wound responses
might be involved in early AMD and the transition to
advanced dry AMD will likely require analysis of RPE
cells in the direct proximity of drusen and the margins
of geographic atrophy.
Conclusions
In the broadest sense, wound responses encompass the
cellular reactions to disruption of normal tissue or cel-
lular architecture. By this definition, wound responses
are inherent components of degenerative disease. Here,
Radeke et al. Genome Medicine  (2015) 7:58 Page 16 of 19we have shown that when RPE cells are subjected to
sustained wound stimulus by impairing the establish-
ment of cell-cell contacts, there is a self-perpetuating
activation of TGFβ pathway that persists even after a
confluent monolayer is reestablished. The net result is
permanent loss of RPE function and establishment of a
chronic state of wound response. Moreover, we show
that there is significant overlap among the genes whose
expression change in the RPE wound response model
and the genes with altered expression in advanced
AMD. Currently, the only therapeutic for the treatment
of AMD is directed at the inhibition of neovasculariza-
tion using function blocking anti-VEGF antibodies.
However, this treatment does not stop the progression
of the non-vascular aspects of the disease [148]. An ap-
proach directed at preventing misappropriate activation
of TGFβ signaling might inhibit the advancement of
AMD in general. In addition, while the focus here has
been on the role of wound response in AMD, these
findings are likely to be relevant to other diseases in-
volving the RPE, such as proliferative vitreoretinopathy,
and epithelial wound responses in general. Moreover,
the potential to extend the effective lifespan of RPE and
perhaps other epithelial cell types in culture through
the use of TGFβ receptor inhibitors is of clear practical
impact with respect to the generation of copious quan-
tities of primary epithelial cells for research or cell-
based therapeutics. In the future it will be interesting to
determine the direct effects of TGFβ ligands on
differentiated RPE monolayers and the potential inter-
play with other aspects of AMD such as oxidative stress
and inflammation.
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